Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 6/20 | 1.00 |
| ▸ | FNTA | P49354 | 13/20 | 0.64 |
| ▸ | FNTB | P49356 | 11/20 | 0.64 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387716 | 1.00 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL83423 | 1.00 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL12640194 | 0.96 | BTN3A1 (0.93) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL12640219 | 0.90 | BTN3A1 (0.81) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL2785835 | 0.86 | BTN3A1 (0.75) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL13176966 | 0.85 | BTN3A1 (0.74) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL8441068 | 0.85 | BTN3A1 (0.74) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL23455692 | 0.84 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL570052 | 0.84 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL12917597 | 0.84 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 900 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137780-A1 | MATERIALS AND METHODS FOR IMPROVED EXPANSION AND USES OF IMMUNE CELLS | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | CleanJoule, Inc. (US) | 2026-04-30 | — | — | US | claimed |
| EP-3856206-B1 | METHODS AND COMPOSITIONS FOR THE EXPANSION AND USE OF ALLOGENEIC GAMMA/DELTA-T CELLS | PHOSPHOGAM INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260000734-A1 | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | IMMATICS US INC (US) | 2026-01-01 | — | — | US | claimed |
| US-12440541-B2 | Methods for expanding and activating γσ T cells for the treatment of cancer and related malignancies | Immatics US, Inc. (US) | 2025-10-14 | — | — | US | claimed |
| WO-2025046256-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A COMBINED CELL POPULATION | UNIVERSITE D'AIX-MARSEILLE (FR) | 2025-03-06 | — | — | WO | claimed |
| US-20250066728-A1 | Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem Cells | Century Therapeutics, Inc. | 2025-02-27 | — | — | US | claimed |
| US-20250034531-A1 | METHOD FOR PRODUCING STEM CELLS | Tanabe, Koji (US) | 2025-01-30 | — | — | US | claimed |
| CN-114555785-B | Method for preparing V-T cell derived exosomes for treating EPSTEIN-bar virus-related cancers | 香港大学 | 2024-12-06 | — | — | CN | claimed |
| CN-118256412-B | Engineering strain of zymomonas mobilis, preparation method and application | 湖北大学 | 2024-09-27 | — | — | CN | claimed |
| WO-2015089349-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2015084721-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-11 | — | — | WO | claimed |
| US-8338173-B2 | Preparation of antigen-presenting human γδ T cells and use in immunotherapy | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-12-25 | — | — | US | claimed |
| US-20090130074-A1 | PREPARATION OF ANTIGEN-PRESENTING HUMAN GAMMA DELTA T CELLS AND USE IN IMMUNOTHERAPY | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2009-05-21 | — | — | US | claimed |
| EP-1761278-B1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2008-12-31 | — | — | EP | claimed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | claimed |
| US-20070218086-A1 | Adjuvant Composition and Methods for Its Use | INNATE PHARMA, S.A. (FR) | 2007-09-20 | — | — | US | claimed |
| EP-1761278-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | Innate Pharma (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | claimed |
| WO-2005102385-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2005-11-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | ERG28, DIMT1, MSMO1 | BTN3A1 4591/4885FNTA 82/4885FNTB 32/4885 |
| US-20070218086-A1 | Adjuvant Composition and Methods for Its Use | CD4, CD69, ICOS | BTN3A1 93/4885FNTA 204/4885FNTB 166/4885 |
| US-20260000734-A1 | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | IL2, IL15RA, IL15 | BTN3A1 1202/4885FNTA 2192/4885FNTB 1485/4885 |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | BTN3A1 875/4885FNTA 2489/4885FNTB 3492/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | BTN3A1 279/4885FNTA 1767/4885FNTB 2156/4885 |
| US-20090130074-A1 | PREPARATION OF ANTIGEN-PRESENTING HUMAN GAMMA DELTA T CELLS AND USE IN IMMUNOTHERAPY | CD4, IFNG, CD74 | BTN3A1 310/4885FNTA 1199/4885FNTB 333/4885 |
| US-20260137780-A1 | MATERIALS AND METHODS FOR IMPROVED EXPANSION AND USES OF IMMUNE CELLS | IL2, IL15, ICOS | BTN3A1 2080/4885FNTA 1783/4885FNTB 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.